Posts by Lee Zou, PhD
-
Tumor Cells Harboring R Loops May Be Excellent Targets for ATR Inhibition
Lee Zou, PhD, of the Cancer Center, and colleagues have uncovered the molecular mechanisms by which cancer cells and other human cells use ATR to cope with R loops in their genomes. Their findings suggest inhibition of ATR may be an effective strategy to selectively kill cancer cells harboring high levels of R loops.
-
Not All Recurrent Mutations Are Cancer Drivers
Mutation frequency can be misleading—DNA "hairpins" are associated with recurrence of cancer mutations outside of known drivers.
-
Mass General Cancer Center Recruits Patients with MDS, CMML for Trial of Novel Drug
Preclinical research at the Massachusetts General Hospital Cancer Center has culminated in a safety trial of an investigational ATR kinase inhibitor in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Biography
Dr. Zou is associate scientific director of Mass General Cancer Center and professor at Harvard Medical School. His research focuses on understanding how cells detect and signal DNA damage and maintain genomic stability.
Mass General Brigham Cancer Institute
Mass General Brigham Cancer Institute unites leading experts and resources across our academic medical centers, making it one of the nation’s top providers of cancer care.